Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread -- Ignore unavailable to you. Want to Upgrade?

To: jj_ who wrote (30740)	1/29/2001 3:15:26 PM
From: Frederick Langford	Read Replies (1) \| Respond to of 49816

BIOI another interesting Biotech BioSource International, Inc. Begins Series of Investment Presentations /FROM PR NEWSWIRE LOS ANGELES 213-626-5500/ TO BUSINESS EDITOR: BioSource International, Inc. Begins Series of Investment Presentations CAMARILLO, Calif., Jan. 29 /PRNewswire/ -- BioSource International, Inc. (Nasdaq: BIOI), began a series of investment presentations today organized by Thomas Weisel Partners and Dain Rauscher Wessels. Senior management of BioSource is meeting with potential and existing investors in New York, Boston, Philadelphia, Minneapolis, San Francisco, San Diego and Los Angeles over a ten day period. The following information describes the presentations including an overview of the Company and its management team, a review of its growth and acquisition strategy and guidance for 2000 estimated results and 2001 projections, and is made pursuant to the Securities and Exchange Commission's fair disclosure rules. Russ Hays, the Company's President and CEO reviewed the Company's objectives of becoming a provider of integrated solutions that accelerate the drug discovery process. Mr. Hays stated that he sees organic growth coming from the continuing investments in infrastructure in its core business, leveraging its existing reagent capability to provide solutions to the high throughput screening portion of the drug discovery market and utilizing its signal transduction products and assay capabilities to provide novel products to the biotech and pharmaceutical markets. Mr. Hays also described the Company's acquisition/partnership strategy to obtain critical mass in key markets and to enable a solutions-based approach to the functional genomics, proteomics and drug discovery markets by acquiring/licensing unique solutions-based products and services. Charles Best, the Company's Chief Financial Officer, discussed the published analysts' forecasts and provided the following guidance: while the results for 2000 are preliminary and subject to audit, estimates reflect a 10.4% increase in sales (13.8% before the impact of foreign exchange) from $29.3 million to $32.3 million. Gross profit margin before one-time items and special charges for 2000 is estimated at approximately 59.5% and operating profit (excluding one-time items and special charges) is estimated at $4.2 million.